Market Intelligence, Clinical Progress, and High-Purity Reagents for Multiple Myeloma and Solid Tumor Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD138 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD138 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View CD138 Products |
| Gene Delivery | CD138 Promise-ORF / Lentivirus Full-length SDC1 ORF for stable cell line generation and cell-based assays. |
View CD138 Products |
| Benchmark Ab | Anti-CD138 (Sequence of Indatuximab / Mezagitamab) Recombinant positive control antibodies for benchmark assays. |
View CD138 Products |
| Validator | CD138 siRNA Set Target-specific knockdown verification in target-expressing cells. |
View CD138 Products |
| Related Target A | BCMA Synergistic plasma cell target; critical for combination therapies and bispecific targeting in multiple myeloma. |
View BCMA Products |
| Related Target B | GPRC5D Next-generation multiple myeloma target; ideal for comparative specificity and dual-targeting screening. |
View GPRC5D Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Shedding Interference (Soluble CD138 decoy) | High-purity recombinant CD138 ECD proteins strictly verified by SDS-PAGE and SEC-HPLC to ensure accurate monomeric/oligomeric state characterization. |
| Conformation & Glycosylation Integrity | HEK293 mammalian expression host ensures native post-translational modifications (heparan sulfate attachment sites) are preserved. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies (biosimilars) available for comparative affinity and internalization assays. |
| False Positives in Cell Assays | Sequence-validated siRNA pools included for target-specific knockdown to confirm assay specificity. |
Live CD138 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD138 therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies to antibody-drug conjugates (ADCs), CAR-T cell therapies, and bispecific antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting CD138 shedding mechanisms, seeking to overcome the decoy effect of soluble CD138 (sCD138) in the tumor microenvironment, and exploring combinations with BCMA or GPRC5D therapeutics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Biotest, NextCure | Multiple Myeloma, Triple-Negative Breast Cancer | Internalization Assay (Requires HEK293-expressed ECD-Fc for high-affinity binding verification) |
| Monoclonal Antibody (mAb) | Takeda (Mezagitamab) | Myeloma, Autoimmune Diseases | Epitope Mapping & Blockade (Requires sequence-verified benchmark antibodies) |
| CAR-T / Cell Therapy | Poseida Therapeutics, Miltenyi Biotec | Relapsed/Refractory Multiple Myeloma | Stable Target Expression (Requires Lentivirus for high-efficiency stable cell line generation) |